Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.

Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics to bring more effective gene therapies and personalized medicines to patients.

Explore Our Pipeline

How we do it

Our ChaESAR Platform

Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.

Learn How

Why we do it

Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs

We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.

About the Science Explore Our Pipeline

rna cancer infectious disease rare genetic disorders
curve seperator

The Latest from Chimeron Bio

in the news

In the News

September 6, 2019

Chimeron Bio Announces Appointment of Dr. Afshin Safavi to Chairman of the Board

Dr. Afshin Safavi is a seasoned entrepreneur and investor in biotechnology, pharmaceutical, IT-technology.

From Our Blog

September 9, 2019

Why Philadelphia for Chimeron Bio

For an early-stage company such as Chimeron Bio, with an innovative gene therapy approach, the right ecosystem is pivotal for its growth and development.

passionate about science

Are you passionate about science and making an impact?

We’re looking for talented individuals to join our team.

Explore Careers